Dr. Roland B. Walter, MD, PhD

Dr. Walter practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Dr. Walter's NPI, 1124139738, was assigned on August 31, 2006. Dr. Walter holds Washington license MD00044240.

Dr. Walter's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Dr. Walter's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. Dr. Walter is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Walter practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Walter's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Walter is board certified in hematology by the American Board of Internal Medicine. Dr. Walter is licensed in Washington.

CMS data shows 377 Medicare services from Dr. Walter across 3 procedure codes in 2024, for 68 Medicare patients. Medicare paid $33,877 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 68 Medicare patients who saw Dr. Walter in 2024. The largest group is 65 to 74, with 41 patients. 74% of them have high blood pressure, and 59% have high cholesterol. 19% are also on Medicaid. Their average risk score is 2.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Walter's median patient age at 63, with 45% women.

In 2017, Dr. Walter wrote 41 Medicare Part D claims. They cover 3 drugs, with $9,995 in total drug cost. In 2016, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Walter for performance year 2024, reported through an alternative payment model (APM). Dr. Walter accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 251 papers to Dr. Walter, published from 2002 to 2025. 2022 was the busiest year, with 20. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols and Hematopoietic Stem Cell Transplantation. Dr. Walter has published most often in Leukemia. Dr. Walter's most frequent co-authors are Anna B. Halpern, MD, Paul Curtis Hendrie, MD, PhD and John Michael Pagel, MD, PhD.

Dmand AI links Dr. Walter to 10 clinical trials, 6 of them phase 1/2 studies. 4 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Blastic Plasmacytoid Dendritic Cell Neoplasm. Fred Hutchinson Cancer Center sponsors the most, 3.

CMS Open Payments shows 134 general payments to Dr. Walter from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 79% of the total. Janssen Research & Development, LLC paid the most, $18,184. It also lists 1 research payment totaling $780 in 2020.